Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q2 FY22 results · Jul–Sep 2021
Wockhardt reported revenue from operations of ₹862.00 crore (up 20.7% from Q2 FY21) and net profit of ₹37.17 crore (up 1029.8% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 862.00 | 714.05 | +20.7% | 859.55 | +0.3% |
| Other income | 5.20 | 16.24 | −68.0% | 1.65 | +215.2% |
| Total income | 867.20 | 730.29 | +18.7% | 861.20 | +0.7% |
| Profit before tax | (29.24) | (85.11) | Loss narrowed | (6.00) | Loss widened |
| Net profit for the period | 37.17 | 3.29 | 11x | (6.58) | Turned profit |
| Attributable to shareholders of the company | 33.53 | 3.55 | +844.5% | (12.71) | Turned profit |
| EPS, basic (₹) | 3.03 | 0.32 | +846.9% | (1.15) | Turned profit |
| Net margin (%) | 4.3 | 0.5 | -0.8 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 310.44 | 294.96 | +5.2% | 278.95 | +11.3% |
| Other income | 4.19 | 14.96 | −72.0% | 3.15 | +33.0% |
| Total income | 314.63 | 309.92 | +1.5% | 282.10 | +11.5% |
| Profit before tax | (89.49) | (87.29) | Loss widened | (77.57) | Loss widened |
| Net profit for the period | (63.70) | (57.38) | Loss widened | (48.69) | Loss widened |
| EPS, basic (₹) | (5.75) | (5.18) | Loss widened | (4.40) | Loss widened |
| Net margin (%) | -20.5 | -19.5 | -17.5 |
Consolidated
- Filed with BSE
- 09 Nov 2021, 13:02 IST
- Board meeting
- 08 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2021, 13:02 IST
- Board meeting
- 08 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE